Evidence map›Paper›PMID 39503828›Full record

ReviewStem cell reviews and reports2025

Can miRNAs in MSCs-EVs Offer a Potential Treatment for Hypoxic-ischemic Encephalopathy?

Hisham Al-Ward, Wei Chen, Wenxia Gao, Chunxue Zhang, Xueyan Yang, Yao Xiong, Xinyi Wang, Rafeq Agila, Hui Xu, Yi Eve Sun

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Target temperature management in acute ischemic stroke.Frontiers in molecular biosciences · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hisham Al-WardStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0003-4087-8275
Wei ChenStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-8375-518X
Wenxia GaoStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Chunxue ZhangStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Xueyan YangStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Yao XiongStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Xinyi WangStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Rafeq AgilaDepartment of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Hui XuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiamusi University, Jiamusi, China. xuhui@jmsu.edu.cn.
Yi Eve SunStem Cell Translational Research Center, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. yi.eve.sun@gmail.com.

Funding

Peak Disciplines (Type IV) of Institutions of Higher Learning in Shanghai Peak Disciplines (Type IV) of Institutions of Higher Learning in ShanghaiThe Key Program of National Natural Science Foundation of China 82030035)
6 · The paper itself

Abstract

Neonatal hypoxic-ischemic encephalopathy (HIE) is a critical condition resulting from impaired oxygen and blood flow to the brain during birth, leading to neuroinflammation, neuronal apoptosis, and long-term neurological deficits. Despite the use of therapeutic hypothermia, current treatments remain inadequate in fully preventing brain damage. Recent advances in mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) offer a novel, cell-free therapeutic approach, as these EVs can cross the blood-brain barrier (BBB) and deliver functional microRNAs (miRNAs) to modulate key pathways involved in inflammation and neuroprotection. This review examines how specific miRNAs encapsulated in MSC-EVs-including miR-21, miR-124, miR-146, and the miR-17-92 cluster-target the complex inflammatory responses that drive HIE pathology. By modulating pathways such as NF-κB, STAT3, and PI3K/Akt, these miRNAs influence neuroinflammatory processes, reduce neuronal apoptosis, and promote tissue repair. The aim is to assess the therapeutic potential of miRNA-loaded MSC-EVs in mitigating inflammation and neuronal damage, thus addressing the limitations of current therapies like therapeutic hypothermia.

Indexed as

Extracellular VesiclesHypoxia-Ischemia, BrainMesenchymal Stem CellsMicroRNAsAnimalsBlood-Brain BarrierHumansMicroRNAsBlood Brain BarrierBrain InjuryExtracellular VesiclesHypoxic Ischemic EncephalopathyMesenchymal stem CellsMiRNAs

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.